Showing 1 - 2 results of 2 for search 'J. Geib', query time: 0.02s Refine Results
  1. 1
    S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

    S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREAT... by M Telen, S Saraf, K Cruz, M Idowu, T Kalfa, I Osunkwo, R Hagar, J Geib, S Forsyth, P Schroeder, E Wu, P Kelly, R Brown

    Published 2022-01-01
    Get full text
    Article
  2. 2
    P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

    P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH by S. Saraf, R. C. Brown, R. W. Hagar, M. Idowu, I. Osunkwo, T. A. Kalfa, F. A. Kuypers, J. Geib, P. Schroeder, E. Wu, P. Kelly, M. J. Telen

    Published 2022-06-01
    Get full text
    Article

Search Tools: